Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Invitae | RCV000553124 | SCV000650887 | uncertain significance | Myofibrillar myopathy 5; Distal myopathy with posterior leg and anterior hand involvement; Hypertrophic cardiomyopathy 26; Dilated Cardiomyopathy, Dominant | 2023-06-24 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on FLNC protein function. ClinVar contains an entry for this variant (Variation ID: 471963). This variant has not been reported in the literature in individuals affected with FLNC-related conditions. The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This sequence change replaces glycine, which is neutral and non-polar, with serine, which is neutral and polar, at codon 406 of the FLNC protein (p.Gly406Ser). |
| Ambry Genetics | RCV002358567 | SCV002657002 | uncertain significance | Cardiovascular phenotype | 2024-01-03 | criteria provided, single submitter | clinical testing | The p.G406S variant (also known as c.1216G>A), located in coding exon 8 of the FLNC gene, results from a G to A substitution at nucleotide position 1216. The glycine at codon 406 is replaced by serine, an amino acid with similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
| Rajaie Cardiovascular, |
RCV002223135 | SCV002499635 | likely pathogenic | Hypertrophic cardiomyopathy 26 | no assertion criteria provided | research | The FLNC gene encodes Filamin C protein in cardiac and skeletal muscle. Due to study of Rene L Begay et al., 2018 (PMID: 30067491), FLNC variants present in 2.2% of Dilated Cardiomyopathy (DCM) families characterized by a high risk of life-threatening ventricular arrhythmias and a pathological cellular phenotype partially overlapping with arrhythmogenic right ventricular cardiomyopathy. |